



**ASX ANNOUNCEMENT**

**6 October 2010**

### **Third VitroGro® Patent Granted in the USA**

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced that the third core patent in the VitroGro® IP family has been granted in the United States and the Deed of Letters Patent received from the United States Patent and Trademark Office.

A total of three VitroGro® patents have now been granted in the USA and one or more VitroGro® patents have also been granted in Japan, South Korea, India, South Africa, Australia and New Zealand.

The CEO of Tissue Therapies, Dr Steven Mercer said, "The granting of this patent is significant because it protects some of the most commercially important aspects of the VitroGro® intellectual property."

"I am particularly please with the progress of the world wide patent examination process and am hopeful of being able to announce further grantings in coming months."

Further information:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)